Head-to-head evidence
Lobeglitazone vs Rosiglitazone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: PPAR-gamma · full Type 2 Diabetes pipeline
Lobeglitazone · Duvie
Developed by Chong Kun Dang Pharmaceutical
NCT02002611 · Phase 1 · completed
Every participant received both lobeglitazone and warfarin, so there is no separate group showing what would have happened without lobeglitazone, and nobody was blinded to treatment. The measures collected were drug-level readings for a drug-interaction check, not a symptom or disease-based result, so this trial offers only limited evidence about lobeglitazone's own effects.
Next expected readout: September 2029 · NCT07108985 (registry estimate)
Rosiglitazone · Avandia
Marketed by GlaxoSmithKline and partners
NCT00279045 · Phase 3 · completed
The study was randomized and compared rosiglitazone with two active treatments in 4,426 participants, but the registry does not describe masking and provides no results for the primary endpoint. Because the outcome is unavailable and the primary measure concerns treatment failure rather than a hard clinical outcome, the evidence is limited despite the large randomized design.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lobeglitazone's landscape · Rosiglitazone's landscape